银屑病系统治疗与恶性肿瘤风险:PSOLAR登记研究
该研究基于PSOLAR登记数据,采用巢式病例对照分析,评估银屑病患者系统治疗与恶性肿瘤风险的关系。共纳入12090例患者,识别252例恶性肿瘤病例并匹配1008例对照。结果显示,长期(≥12个月)使用TNF-α抑制剂与恶性肿瘤风险增加相关,而甲氨蝶呤和乌司奴单抗未显示风险增加。
要点
- 长期(≥12个月)TNF-α抑制剂治疗与银屑病患者恶性肿瘤风险增加相关。
- 甲氨蝶呤或乌司奴单抗治疗未显示恶性肿瘤风险增加。
- 短期TNF-α抑制剂治疗未观察到风险增加。
核心结论
- 长期(≥12个月)TNF-α抑制剂治疗可能增加银屑病患者恶性肿瘤风险,而甲氨蝶呤和乌司奴单抗未显示风险增加。
研究设计与样本
- 在PSOLAR登记中开展巢式病例对照分析,纳入无恶性肿瘤史的银屑病患者,病例为首次恶性肿瘤(非黑色素瘤皮肤癌除外),对照按年龄、性别、地理区域和登记时间匹配。
主要发现
- 共纳入12090例患者,识别252例恶性肿瘤病例,匹配1008例对照。
- 甲氨蝶呤或乌司奴单抗治疗(>0至<3个月、3至<12个月、≥12个月)与未暴露相比,恶性肿瘤风险未增加。
关键数值与推荐
- 甲氨蝶呤或乌司奴单抗治疗(>0至<3个月、3至<12个月、≥12个月)与未暴露相比,未显示恶性肿瘤风险增加。
临床怎么用
- 对需长期使用TNF-α抑制剂的银屑病患者,应评估恶性肿瘤风险并加强监测。
- 甲氨蝶呤或乌司奴单抗治疗期间,恶性肿瘤风险未见显著增加。
局限性
- 病例和对照可能属于一个或多个治疗类别。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The effect of systemic therapy on malignancy risk among patients with psoriasis is not fully understood. OBJECTIVE: Evaluate the impact of systemic treatment on malignancy risk among patients with psoriasis in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). METHODS: Nested case-control analyses were performed among patients with no history of malignancy. Cases were defined as first malignancy (other than nonmelanoma skin cancer) in the Psoriasis Longitudinal Assessment and Registry, and controls were matched by age, sex, geographic region, and time on registry. Study therapies included methotrexate, ustekinumab, and tumor necrosis factor-α (TNF-α) inhibitors. Exposure was defined as 1 or more doses of study therapy within 12 months of malignancy onset and further stratified by duration of therapy. Multivariate conditional logistic regression, adjusted for potential confounders, was used to estimate odds ratios of malignancies associated with therapy. RESULTS: Among 12,090 patients, 252 malignancy cases were identified and 1008 controls were matched. Treatment with methotrexate or ustekinumab for more than 0 months to less than 3 months, 3 months to less than 12 months, or 12 months or longer was not associated with increased malignancy risk versus no exposure. Longer-term (≥12 months) (odds ratio, 1.54; 95% confidence interval, 1.10-2.15; P = .01), but not shorter-term treatment, with a TNF-α inhibitor was associated with increased malignancy risk. LIMITATIONS: Cases and controls could belong to 1 or more therapy categories. CONCLUSIONS: Long-term (≥12 months) treatment with a TNF-α inhibitor, but not methotrexate and ustekinumab, may increase risk for malignancy in patients with psoriasis.
引用
- Fiorentino D, Ho V, Lebwohl MG, et al. Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry. J Am Acad Dermatol. 2017. PMID: 28893407. doi:10.1016/j.jaad.2017.07.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。